Prof Peter-Phillip de Cruz
Professorial Fellow, Gastroenterology
Department of Medicine
395 Scholarly works
5 Projects
HIGHLIGHTS
2026
Journal article
Impact of BECLIN1 haploinsufficiency on goblet cell function and susceptibility to colitis
DOI: 10.1038/s41419-026-08984-82026
Journal article
2024
Research grants (ARC, NHMRC, MRFF)
Mathematical and Computational Methods for Precision Medicine in Acute Severe Ulcerative Colitis
2022
Research grants (ARC, NHMRC, MRFF)
Improving Outcomes in Inflammatory Bowel Disease: A Multifaceted Program of Research
2021
Research grants (ARC, NHMRC, MRFF)
A Prospective Randomised Controlled Trial of Adults With Perianal Fistulising Crohn\2019s Disease and Optimised Therapeutic Infliximab Levels: PROACTIVE Trial
2016
Journal article
Intestinal Failure and Transplant: The Australian Experience (2009 to 2014)
DOI: 10.1016/j.transproceed.2015.09.0712015
Journal article
Crohn's disease management after intestinal resection: A randomised trial
DOI: 10.1016/S0140-6736(14)61908-5
RECENT SCHOLARLY WORKS
2026
Journal article
Rethinking the dose: A Bayesian meta-analysis of infliximab intensification in acute severe ulcerative colitis
DOI: 10.1093/ibd/izag0422026
Journal article
Value‐Based Health Care—Protecting the Future of IBD Care or Pipedream?
DOI: 10.1002/jcc5.700542026
Journal article
Never‐Smoking Is Associated With Histologic Remission in Ulcerative Colitis: A Post‐Hoc Analysis of the VIEWS Randomised Controlled Trial
DOI: 10.1002/jcc5.700512026
Journal article
2026
Journal article
Reliability and Responsiveness of Endoscopic Indices for Assessing Crohn’s Disease Postoperative Recurrence in the PREVENT Trial
DOI: 10.1016/j.cgh.2025.08.0212026
Journal article
980 RANDOMISED CONTROLLED TRIAL OF CONTINUED INTRAVENOUS VERSUS SWITCHING TO SUBCUTANEOUS INFLIXIMAB IN INFLAMMATORY BOWEL DISEASE: THE SUBCUTANEOUS INFLIXIMAB SWITCH STUDY (SISS).
DOI: 10.1016/s0016-5107(26)02347-32026
Journal article
Extended High-Dose Tofacitinib Induction Improves Clinical Response in Ulcerative Colitis: A Multicenter Cohort Study
DOI: 10.1002/jgh3.704102026
Journal article
980 RANDOMISED CONTROLLED TRIAL OF CONTINUED INTRAVENOUS VERSUS SWITCHING TO SUBCUTANEOUS INFLIXIMAB IN INFLAMMATORY BOWEL DISEASE: THE SUBCUTANEOUS INFLIXIMAB SWITCH STUDY (SISS).
DOI: 10.1016/s0016-5085(26)02416-9